“If I was worried about fiscal year 2023 in terms of delivering on what we’re going to do, then I shouldn’t be sitting in this chair, to be honest. This is a long lead time business – I have to think about it 10 years from now because nobody else is.”
a bit further down the track and CSL holding up well (a bit hard comparing it to the index when it is quite a significant element of the composition)CSL fully participated in the since-June rally, then instead of falling away like many others in August it just coiled up.
"There is a lot more to this business than just viewing it as an earnings erosion story following loss of exclusivity,” Perreult said. “I thought plasma manufacturing was hard, iron is harder. In many ways it’s similar to plasma – it’s gunky, it’s unloved and has a complex manufacturing process which is very difficult to replicate. “There are enormous opportunities to grow the iron franchise – to drive new indications, expand into new geographies and improve access."
“Now we’ve gotten into pathway medicine, it’s become tricker, but the fact we’ve maintained that [91 per cent] says that we’re choosing wisely, and we’re taking bets where it makes sense, and not for no reason at all. “But we’re 40 years into [plasma products] and we haven’t seen peak sales yet, which is remarkable. What that does for an organisation, this kind of predictable sales, is it allows us not to panic.
“I don’t care what news you read, Merck, J&J, they’re looking for ways to replace the lost revenue from some blockbuster product... they start to make bets that maybe they wouldn’t make [otherwise], and there’s a hidden impetus to overreach. The plasma business keeps us from making panicked decisions.”
Good evening peter2It's been a long three years for CSL investors while price has traded in this large $100 range.
In the medium term CSL looks likely to hit $300 again soon. Then it'll move slowly to new all time highs. Monthly chart posted.
View attachment 149556
Hello Captain_ChazaWe all Learn the Hard Way
I once had a few CSL @ ~$ 2.00ea in the days when we all always only had a "few "
My broker advised me to sell @ ~$6.00
He said
" You can't go broke taking profits"
Well, He was so very very WRONG!!!
I ended up losing my first Ship
View attachment 149561
That is what I call "Learning the Hard Way"
No further comment needed.US drug regulators have approved a one-off gene-therapy treatment for adults with the genetic blood disorder hemophilia B that frees patients from repeated treatments but costs $3.5m a dose, making it the most expensive medicine in the world.
The US Food and Drug Administration (FDA) approved CSL Behring’s hemophilia B gene therapy Hemgenix on Tuesday. It cuts the number of bleeding events expected over the course of a year by over half, a study found, and frees 94% of patients from the need for regular infusions to control the condition.
“Gene therapy for hemophilia has been on the horizon for more than two decades,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. Marks said the approval “represents important progress in the development of innovative therapies for those experiencing a high burden of disease associated with this form of hemophilia”.
Hemophilia B represents 15% of hemophilia patients, occurs mostly in men and is prevalent in about one in 40,000 of the population. Women who carry the disease often have no symptoms.
I'll say no moreEtranaDez looks poised to become the world’s first gene therapy for haemophilia B. CSL expects a decision from the US Food and Drug Administration in late November, with the therapy having been accepted for priority review. If it is approved, Dr Mezzanotte said it would hit the market in the first quarter of calendar year 2023. Analysts expect the therapy could sell for $US2 million-plus for a single dose.
No further comment needed.
Mick
OOPS!I'll say no more
All good, what I like is that they said it would happen, and it does. On timeOOPS!
All good, what I like is that they said it would happen, and it does. On time
So, who's going to cough up $2+ mill for a single dose ... only a National Health scheme/ PBS? The maths must be that ongoing medical care must be more, for a subset of potential patients. I wonder who gets to play God?
good on ya dyna for having a chop. Difficult to tame, CSL, most dynamic beast. rcw1 likes to have a play anywhere btw $250 and $270.Here we go. I must be the only d*ck on this forum to pay 300 bucks for a single share.
Got 10 grand worth at $278 , bang on opening this morning.
As they say in the classics ... " It's a start "
Ain't got a clue where to enter for the next hit, though.
It's all in the charts, they say.
Can't see a damned thing.
Blind.....as......a......bat.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?